Categories:
Heart News,
Scientific Conferences & Meetings
|
Published: May 20, 2021
Gender-affirming hormone therapy may not increase CVD risk for transgender adolescents
American Heart Association Epidemiology, Prevention, Lifestyle & Cardiometabolic Health Conference – Presentation MP65